Authorized purpose: Support trained medical professionals in processing, visualizing, editing, and interpreting prostate MR studies, including structured PI-RADS scoring; diagnosis must not be made solely from the software analysis.
Clinical role
User-in-the-loop post-processing and structured interpretation aid: automatic input checks, registration, segmentation, and combination-image generation are followed by user editing, lesion analysis, PI-RADS workflow, report creation, and export.
Images and patients
MRI · Prostate, prostatic sub-regions, and user-selected potential lesions.
Key limitation
Keep in mind: Use is by trained medical professionals, and diagnosis must not rely solely on the analysis. Segmentations and ROI initializations are editable by the user. Prostate segmentation clinical performance was not repeated for this update; clinical testing of sub-region segmentation and ROI localization was qualitative using a five-point radiologist Likert scale. The packet does not establish sensitivity, specificity, or diagnostic AUC.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Support trained medical professionals in processing, visualizing, editing, and interpreting prostate MR studies, including structured PI-RADS scoring; diagnosis must not be made solely from the software analysis.
Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Prostate, prostatic sub-regions, and user-selected potential lesions. Input: Prostate multiparametric MRI data sets; the reviewed FDA text does not specify the complete sequence, protocol, or input-interface requirements.
Who uses it?Intended users: Trained medical professionals.
What does the software produce?Output: Registered multiparametric and biparametric combination views; prostate and sub-region segmentations; volume and PSA-density measurements; user-edited segmentations; potential-lesion segmentation and analysis; PI-RADS scoring; 3D secondary-capture segmentations; a PDF report; and DICOM output.
What is its most important limitation?Key limitation: Use is by trained medical professionals, and diagnosis must not rely solely on the analysis. Segmentations and ROI initializations are editable by the user. Prostate segmentation clinical performance was not repeated for this update; clinical testing of sub-region segmentation and ROI localization was qualitative using a five-point radiologist Likert scale. The packet does not establish sensitivity, specificity, or diagnostic AUC.
Clinical takeaway. Clinical role: Support trained medical professionals in processing, visualizing, editing, and interpreting prostate MR studies, including structured PI-RADS scoring; diagnosis must not be made solely from the software analysis.
Evidence takeaway. Evidence from the reviewed source record: FDA K230772 describes nonclinical bench testing that compared automatic prostate/sub-region segmentations with ground truth using Dice overlap and mean surface distance, with inter-observer comparisons. Clinical performance testing of sub-region segmentations and ROI localization was qualitative, using radiologist five-point Likert scores; the updated prostate-segmentation clinical test was not repeated because nonclinical performance was at least as accurate as the predicate. The updated algorithms were trained on more than 400 scans. No FDA sensitivity, specificity, diagnostic AUC, or general accuracy percentage is established.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Support trained medical professionals in processing, visualizing, editing, and interpreting prostate MR studies, including structured PI-RADS scoring; diagnosis must not be made solely from the software analysis.
User-in-the-loop post-processing and structured interpretation aid: automatic input checks, registration, segmentation, and combination-image generation are followed by user editing, lesion analysis, PI-RADS workflow, report creation, and export.
Registered multiparametric and biparametric combination views; prostate and sub-region segmentations; volume and PSA-density measurements; user-edited segmentations; potential-lesion segmentation and analysis; PI-RADS scoring; 3D secondary-capture segmentations; a PDF report; and DICOM output.
Use is by trained medical professionals, and diagnosis must not rely solely on the analysis. Segmentations and ROI initializations are editable by the user. Prostate segmentation clinical performance was not repeated for this update; clinical testing of sub-region segmentation and ROI localization was qualitative using a five-point radiologist Likert scale. The packet does not establish sensitivity, specificity, or diagnostic AUC.
FDA K230772 describes nonclinical bench testing that compared automatic prostate/sub-region segmentations with ground truth using Dice overlap and mean surface distance, with inter-observer comparisons. Clinical performance testing of sub-region segmentations and ROI localization was qualitative, using radiologist five-point Likert scores; the updated prostate-segmentation clinical test was not repeated because nonclinical performance was at least as accurate as the predicate. The updated algorithms were trained on more than 400 scans. No FDA sensitivity, specificity, diagnostic AUC, or general accuracy percentage is established.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA K230772 describes nonclinical bench testing that compared automatic prostate/sub-region segmentations with ground truth using Dice overlap and mean surface distance, with inter-observer comparisons. Clinical performance testing of sub-region segmentations and ROI localization was qualitative, using radiologist five-point Likert scores; the updated prostate-segmentation clinical test was not repeated because nonclinical performance was at least as accurate as the predicate. The updated algorithms were trained on more than 400 scans. No FDA sensitivity, specificity, diagnostic AUC, or general accuracy percentage is established.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Quantib Prostate regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K230772
IndependenceIndependence not established
K230772
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K230772. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Prostate multiparametric MRI data sets; the reviewed FDA text does not specify the complete sequence, protocol, or input-interface requirements.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: DICOM output, 3D secondary captures, and a PDF report are described; the packet does not establish a specific PACS, RIS, EHR, input interface, routing behavior, or interface version.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-09 ·
Returned objects
Source context, not route validation: Registered multiparametric and biparametric combination views; prostate and sub-region segmentations; volume and PSA-density measurements; user-edited segmentations; potential-lesion segmentation and analysis; PI-RADS scoring; 3D secondary-capture segmentations; a PDF report; and DICOM output.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Registered multiparametric and biparametric combination views; prostate and sub-region segmentations; volume and PSA-density measurements; user-edited segmentations; potential-lesion segmentation and analysis; PI-RADS scoring; 3D secondary-capture segmentations; a PDF report; and DICOM output.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
DICOM output, 3D secondary captures, and a PDF report are described; the packet does not establish a specific PACS, RIS, EHR, input interface, routing behavior, or interface version.
ACR AI Central provides an exact-submission model card for Quantib Prostate; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
22Fields reviewed
9Source classes checked
4Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 4 PubMed and 1 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 4 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K230772 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Deployment: Not verified - checked 2026-09-09 - Exact FDA submission
The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-09 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Concurrent-reading aid for trained physicians detecting and characterizing prostate-cancer lesions in adult males aged 40 years and older undergoing prostate MRI.
Modality
MRI
Anatomy
Prostate and lesions within or extending from the prostate
Authorized purpose: SIGNA Bolt is a whole-body MRI system for high-resolution diagnostic imaging of the labeled body regions, with supported AI-assisted reconstruction, positioning, and protocol functions.
Authorized purpose: SIGNA Sprint Select is a whole-body MRI system for diagnostic imaging of the labeled body regions, with supported AI-assisted reconstruction, positioning, and protocol functions.
Authorized purpose: SIGNA Sprint is a 1.5T whole-body MRI system for diagnostic imaging of the labeled head, neck, TMJ, spine, breast, heart, abdomen, pelvis, joints, prostate, vessels, and musculoskeletal regions.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.